摘要
目的探讨乳腺肿块患者血清和肿块组织中B细胞淋巴瘤因子3(Bcl-3)蛋白的表达及临床意义。方法选择2017年12月至2019年3月新乡医学院第三附属医院收治的56例乳腺肿块患者为研究对象,患者术前均未接受化学治疗、放射治疗,所有乳腺肿块组织行病理学检查,根据病理学检查结果将患者分为非肿瘤组(包括乳腺炎、乳腺导管扩张症、乳腺增生症、脂膜炎、乳腺腺病)12例、良性肿瘤组(包括乳腺腺病伴导管内乳头状瘤、纤维腺瘤、纤维脂肪瘤、乳腺腺病伴纤维腺瘤、乳腺导管内乳头状瘤)24例、恶性肿瘤组(包括乳腺浸润性小叶癌、乳腺浸润性导管癌、非特殊型浸润性癌)20例;采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶法检测肿块组织中Bcl-3蛋白的表达,酶联免疫吸附试验检测患者血清中Bcl-3蛋白水平。结果非肿瘤组、良性肿瘤组、恶性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率分别为16.67%(2/12)、54.17%(13/24)和85.00%(17/20);恶性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率显著高于良性肿瘤组和非肿瘤组(χ^(2)=4.781、14.521,P<0.05),良性肿瘤组患者肿块组织中Bcl-3蛋白阳性表达率显著高于非肿瘤组(χ^(2)=4.629,P<0.05)。非肿瘤组、良性肿瘤组、恶性肿瘤组患者血清中Bcl-3蛋白水平分别为(48.10±23.03)、(34.75±17.93)、(22.50±18.29)μg·L^(-1);恶性肿瘤组患者血清中Bcl-3蛋白水平显著低于良性肿瘤组和非肿瘤组(t=2.186、3.367,P<0.05),良性肿瘤组患者血清中Bcl-3蛋白水平显著低于非肿瘤组(t=1.865,P<0.05)。结论乳腺癌组织中Bcl-3蛋白表达上调,乳腺癌患者血清中Bcl-3蛋白水平降低,检测Bcl-3蛋白表达可能为乳腺癌的诊断提供参考。
Objective To investigate the expression of B-cell lymphoma factor 3(Bcl-3)protein in serum and breast mass tissues and its clinical significance.Methods A total of 56 patients with breast mass admitted to the Third Affiliated Hospital of Xinxiang Medical University from December 2018 to March 2019 were selected as the research subjects.None of the patients received chemotherapy or radiotherapy before surgery.All breast mass tissues of the patients were examined by pathology.According to the pathology examination results,the patients were divided into the the tumor group(including mastitis,mammary duct ectasia,breast hyperplasia,panniculitis,breast adenosis;n=12),benign tumor group(including breast adenosis with intraductal papilloma,fibroadenoma,fibrolipoma,breast adenosis with fibroadenoma,breast intraductal papilloma;n=24)and malignant tumor group(including invasive lobular carcinoma of the breast,invasive ductal carcinoma of breast,nonspecific invasive carcinoma).The expression of Bcl-3 protein in breast mass tissues was detected by immunohistochemical Streptomyces antibiotin protein-peroxidase assay,and the serum Bcl-3 protein level of patients was detected by enzyme linked immunosorbent assay.Results The positive expression rate of Bcl-3 protein in breast mass tissues of patients in the non-tumor group,benign tumor group and malignant tumor group was 16.67%(2/12),54.17%(13/24)and 85.00%(17/20),respectively.The positive expression rate of Bcl-3 protein in breast mass tissues of patients in the malignant tumor group was significantly higher than that in the non-tumor group and benign tumor group(χ^(2)=4.781,14.521;P<0.05),the positive expression rate of Bcl-3 protein in breast mass tissues of patients in the benign tumor group was significantly higher than that in the non-tumor group(χ^(2)=4.629,P<0.05).The serum Bcl-3 protein level of patients in the non-tumor group,benign tumor group and malignant tumor group was(48.10±23.03),(34.75±17.93),(22.50±18.29)μg·L^(-1),respectively.The serum Bcl-3 protein le
作者
王妍妍
赵永新
王建强
康丽霞
王辉
WANG Yanyan;ZHAO Yongxin;WANG Jianqiang;KANG Lixia;WANG Hui(Department of Clinical Laboratory,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China;Department of Pathology,the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China;School of Laboratory Medicine,Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
出处
《新乡医学院学报》
CAS
2021年第7期649-652,共4页
Journal of Xinxiang Medical University
基金
河南省高校科技创新团队支持计划项目(编号:15IRTSTHN025)。
